Back to Results
First PageMeta Content



12 Weeks Isoniazid & Rifapentine (3HP) Benefits, Challenges & Additional Opportunities John W. Wilson, MD FIDSA Associate Professor of Medicine Division of Infectious Diseases Mayo Clinic, Rochester MN
Add to Reading List

Document Date: 2016-04-25 14:02:00


Open Document

File Size: 1,70 MB

Share Result on Facebook
UPDATE